Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 1.66B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -154.81M |
| Shares Out | 55.18M |
| EPS (ttm) | -2.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 239,457 |
| Open | 31.18 |
| Previous Close | 30.79 |
| Day's Range | 29.94 - 31.32 |
| 52-Week Range | 13.15 - 44.75 |
| Beta | 1.76 |
| Analysts | Buy |
| Price Target | 56.74 (+88.94%) |
| Earnings Date | May 2, 2023 |
About KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-muta... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $56.74, which is an increase of 88.94% from the latest price.
News
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
WATERTOWN, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small ...
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.26% and 37.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the ...
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
Company also presenting at upcoming investor conferences Company also presenting at upcoming investor conferences
X-Chem and Kymera Expand Existing Partnership
WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc....
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel s...
All You Need to Know About Kymera Therapeutics, Inc. (KYMR) Rating Upgrade to Buy
Kymera Therapeutics, Inc. (KYMR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
WATERTOWN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel s...
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m...
7 Perfect Presents to Gift Your 2023 Stock Portfolio
New Year 2023 will see a continued tightening of monetary policy as the Federal Reserve attempts to rein in sky-high inflation. Following the 50 basis point rate hike in Dec., there are expectations t...
Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474
Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.
Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today?
What's trending in the pharmaceutical sector today? In a fresh press release, Kymera Therapeutics (NASDAQ: KYMR) disclosed positive results from its clinical trial for a skin condition treatment the ...
Kymera's stock rallies as it plans to move treatment into Phase 2 studies next year
Shares of Kymera Therapeutics Inc. KYMR, -7.68% rallied about 35% in premarket trading on Wednesday after the company shared positive data from a Phase 1 clinical trial evaluating the treatment it's d...
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi's Decision to Advance KT-474 into Phase 2 Clinical Trials
KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favor...
Preclinical Data from Kymera Therapeutics' Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting
Activity of STAT3 degrader in preclinical model of cutaneous T-cell lymphoma (CTCL) validates selective STAT3 degradation as a potential therapeutic strategy for STAT3-driven T cell malignancies
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -12.86% and 41.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
Completed patient cohort portion (Part C) of the IRAK4 degrader KT-474 Phase 1 trial
Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors
WATERTOWN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m...
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
Company also presenting at upcoming investor conferences Company also presenting at upcoming investor conferences
Kymera Therapeutics, Inc. (KYMR) Moves 9.6% Higher: Will This Strength Last?
Kymera Therapeutics, Inc. (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in ...
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphoma is the second orphan drug designation for KT-333 Cutaneous T-Cell Lymphoma is the second orphan drug designation for KT-333
Kymera Therapeutics to Participate in Upcoming September Conferences
WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m...